On Tuesday, Ibio Inc (NYSEMKT:IBIO)’s shares declined -6.19% to $0.890.
Ibio Inc (IBIO) declared the issue of a new U.S. patent expanding the company’s iBioModulator™ thermostable immunomodulator protein portfolio. The new patent, serial number 9,012,199, is entitled “Recombinant Carrier Molecule for Expression, Delivery, and Purification of Target Polypeptides.” The fundamental composition of matter claims grant iBio important exclusivity over new, modified carrier molecules derived from the company’s proprietary iBioModulator™ thermostable immunomodulator protein system and their use with one or more target proteins or antigens.
iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies comprise iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that enhances the potency and duration of the effect of prophylactic and therapeutic vaccines.
Viggle Inc (NASDAQ:VGGL)’s shares dropped -6.01% to $2.66.
Viggle Inc (VGGL) has planned a conference call on Monday, May 11, 2015 at 9:00 A.M. Eastern Time (ET) to review results for the fiscal 2015 third quarter ended March 31, 2015.
Viggle Inc. operates as a mobile and Web-based entertainment marketing platform for media companies, brands, and consumers in the United States. It guides users towards various forms of media consumption with television enhancement, music discovery, entertainment content publishing, and distributed viewing reminders.
At the end of Tuesday’s trade, TherapeuticsMD Inc (NYSEMKT:TXMD)‘s shares dipped -6.00% to $6.42.
TherapeuticsMD Inc (TXMD) declared its first quarter financial results for the period ended March 31, 2015.
First quarter and recent corporate developments
Net revenue raised to about $4.5 million for the quarter ended March 31, 2015, contrast with about $2.8 million for the quarter ended March 31, 2014.
Net loss was about $20.9 million for the quarter ended March 31, 2015, contrast with about $9.2 million for the quarter ended March 31, 2014, reflecting raised costs associated with the company’s continued enrollment of patients in two phase 3 clinical trials for its novel hormone therapy product candidates.
TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, counting prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, in addition to duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.
FormFactor, Inc. (NASDAQ:FORM), ended its Tuesday’s trading session with -5.97% loss, and closed at $8.19.
FormFactor, Inc. (FORM) declare its participation in the 16th Annual Investor Conference at Loews Hollywood Hotel, Los Angeles, on May 13, 2015, 9:30 am Pacific Time.
The company’s Chief Executive Officer, Mike Slessor, will present. The public is invited to listen to a live webcast of FormFactor’s presentation, which can be accessed from the investors’ section of the company’s website at www.formfactor.com. Replays of the webcast will also be accessible at www.formfactor.com.
FormFactor, Inc. designs, develops, manufactures, sells, and supports semiconductor probe card products and solutions worldwide. The company’s probe cards are used to perform wafer test, which is the testing of the semiconductor die or chips on the semiconductor wafer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
